ArticleNutrients2019
Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.
Open access · goldAbstract read
In one paragraph
Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity.FEBS open bio · 2026Article
- Lipid Remodeling and Metabolic Adaptation in Cancer Cell Membranes: A Platform for Membrane-Targeted Nanotherapy.Advances in experimental medicine and biology · 2026Review
- A Review on Hepatoprotective Effect of Chrysin: Preclinical Implications and Molecular Cascades Came into Focus.Current diabetes reviews · 2026Review
- Metabolic Functions and Mechanisms of Selenium, Selenocysteine, and GPX4 Mediated Immune Regulation Through Autophagy in Solid Tumors.Food science & nutrition · 2025Review
- Chrysin-Loaded Micelles Regulate Cell Cycle and Induce Intrinsic and Extrinsic Apoptosis in Ovarian Cancer Cells.Nanomaterials (Basel, Switzerland) · 2025Article
- Chrysin: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM).Cancer gene therapy · 2025Article
- Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells.Bioscience reports · 2024Article
- HAntioxidants (Basel, Switzerland) · 2023Article
- Recent advances in the role of endogenous hydrogen sulphide in cancer cells.Cell proliferation · 2023Review
- The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer.International journal of molecular sciences · 2023Review
- The mechanisms crosstalk and therapeutic opportunities between ferroptosis and ovary diseases.Frontiers in endocrinology · 2023Review
- Cystathionine β-synthase affects organization of cytoskeleton and modulates carcinogenesis in colorectal carcinoma cells.Frontiers in oncology · 2023Article
- Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers.Biomolecules · 2022Review
- Emerging roles of cystathionine β-synthase in various forms of cancer.Redox biology · 2022Review
- Current progress of ferroptosis study in ovarian cancer.Frontiers in molecular biosciences · 2022Review
- Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer.Frontiers in immunology · 2022Review
- Expression profiles and prognostic values of BolA family members in ovarian cancer.Journal of ovarian research · 2021Article
- Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin.Cancer cell international · 2021Review
- Cysteine metabolic circuitries: druggable targets in cancer.British journal of cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Inês SantosCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. ips.ines95@gmail.com.
Cristiano RamosCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. ramos.cristiano.93@gmail.com.ORCID 0000-0002-3822-2835
Cindy MendesCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. cindymendes8@gmail.com.
Catarina O SequeiraCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. catarina.sequeira@nms.unl.pt.
Catarina S ToméInstituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Avenida da República (EAN), 2780-157 Oeiras, Portugal. ctome@itqb.unl.pt.ORCID 0000-0002-8456-4078
Dalila G H FernandesInstituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Avenida da República (EAN), 2780-157 Oeiras, Portugal. dalilagfhf@itqb.unl.pt.
Pedro MotaCQFM-IN and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal. pedromb.mota@gmail.com.ORCID 0000-0002-7874-2974
Rita F PiresCQFM-IN and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal. ritafpires@tecnico.ulisboa.pt.ORCID 0000-0003-3678-1462
Donato UrsoCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. ursodonato@gmail.com.
Ana HipólitoCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. anaritac.hipolito@gmail.com.
Alexandra M M AntunesCentro de Química Estrutural, Instituto Superior Técnico, ULisboa, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal. alexandra.antunes@tecnico.ulisboa.pt.ORCID 0000-0003-1827-7369
João B VicenteInstituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Avenida da República (EAN), 2780-157 Oeiras, Portugal. jvicente@itqb.unl.pt.
Sofia A PereiraCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. sofia.pereira@nms.unl.pt.ORCID 0000-0002-8456-9995
Vasco D B BonifácioCQFM-IN and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal. vasco.bonifacio@tecnico.ulisboa.pt.ORCID 0000-0003-2349-8473
Sofia C NunesCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. asofianunes5@gmail.com.
Jacinta SerpaCEDOC, Chronic Diseases Research Centre, NOVA Medical School|Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal. jacinta.serpa@nms.unl.pt.ORCID 0000-0002-1548-5907
Instituto Português de Oncologia de Coimbra Francisco Gentil · PTInstituto de Biologia Experimental e Tecnológica · PTUniversity of Lisbon · PTUniversidade Nova de Lisboa · PTInstituto Superior Técnico · PT
Funding
iNOVA4Health, FCT and European Union's Horizon 2020 PTDC/MEC-ONC/29327/2017 and grant agreement No 810856
Abstract
Ovarian cancer is the main cause of death from gynecological cancer, with its poor prognosis mainly related to late diagnosis and chemoresistance (acquired or intrinsic) to conventional alkylating and reactive oxygen species (ROS)-generating drugs. We and others reported that the availability of cysteine and glutathione (GSH) impacts the mechanisms of resistance to carboplatin in ovarian cancer. Different players in cysteine metabolism can be crucial in chemoresistance, such as the cystine/glutamate antiporter system Xc (xCT) and the H
Indexed as
Antineoplastic AgentsCell Line, TumorCell SurvivalCystathionine beta-SynthaseDendrimersFemaleFlavonoidsGlutathioneHumansNanostructuresOvarian NeoplasmsPolymersSeleniumAntineoplastic AgentschrysinCystathionine beta-SynthaseDendrimersFlavonoidsGlutathionePolymerspolyureaSeleniumcystathionine β-synthase (CBS)cysteinecystine/glutamate antiporter system Xc- (xCT)folate-targeted polyurea dendrimersglutathione (GSH)hydrogen sulfide (H2S)ovarian cancerplatinum drugsselenium chrysin (SeChry)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.